Skip to content
10-Q

Quarterly Report

XERIS PHARMACEUTICALS INC

0001346302-21-000046

← back to feed
Filed
May 13, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · Apr 30, 2021 66.36M sh
Capex Q1 2021 · Mar 31, 2021 $429K
Capex restated Q1 2021 · Mar 31, 2020 $26K
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$23.96M
Operating Cash Flow Q1 2021 · Mar 31, 2020 −$28.95M
Short Term Investments Q1 2021 · Mar 31, 2021 $69.29M
Short Term Investments Q1 2021 · Dec 31, 2020 $96.19M
Cash And Equivalents Q1 2021 · Mar 31, 2021 $66.6M
Cash And Equivalents Q1 2021 · Dec 31, 2020 $37.6M
Cash And Equivalents Q1 2021 · Mar 31, 2020 $39.24M
Cash And Equivalents Q1 2021 · Dec 31, 2019 $19.52M
Stockholders Equity Q1 2021 · Mar 31, 2021 $44.39M
Stockholders Equity Q1 2021 · Dec 31, 2020 $33.76M
Stockholders Equity Q1 2021 · Mar 31, 2020 $27.07M
Stockholders Equity Q1 2021 · Dec 31, 2019 $14.44M
Current Liabilities Q1 2021 · Mar 31, 2021 $27.42M
Current Liabilities Q1 2021 · Dec 31, 2020 $28.21M
Total Liabilities Q1 2021 · Mar 31, 2021 $123.25M
Total Liabilities Q1 2021 · Dec 31, 2020 $125.39M
Current Assets Q1 2021 · Mar 31, 2021 $160.63M
Current Assets Q1 2021 · Dec 31, 2020 $152.21M
Total Assets Q1 2021 · Mar 31, 2021 $167.64M
Total Assets Q1 2021 · Dec 31, 2020 $159.15M
Sga Expense Q1 2021 · Mar 31, 2021 $19.08M
Sga Expense Q1 2021 · Mar 31, 2020 $21.61M
Rd Expense Q1 2021 · Mar 31, 2021 $4.03M
Rd Expense Q1 2021 · Mar 31, 2020 $6.65M
Net Income Q1 2021 · Mar 31, 2021 −$18.41M
Net Income Q1 2021 · Mar 31, 2020 −$29.18M
Operating Income Q1 2021 · Mar 31, 2021 −$16.74M
Operating Income Q1 2021 · Mar 31, 2020 −$28.25M
Gross Profit Q1 2021 · Mar 31, 2021 $6.37M
Gross Profit Q1 2021 · Mar 31, 2020 −$2K
Revenue Q1 2021 · Mar 31, 2021 $8.05M
Revenue Q1 2021 · Mar 31, 2020 $1.68M